Form 483

Daiichi Sankyo Europe GmbH Form 483, 2025-07-18

FDA issued a Form 483 to Daiichi Sankyo Europe GmbH on 2025-07-18 with 3 public-safe observations.

483· Form 483 issuedHuman Drugs3 observations

Daiichi Sankyo Europe GmbH · Pfaffenhofen A.D.Ilm, Germany · Issued July 18, 2025

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

18 Jul 2025
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Joseph A Piechocki

18 Jul 2025
21 CFR 211.194(a)

Complete test data included in records

Cited by Joseph A Piechocki

18 Jul 2025
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Joseph A Piechocki

Inspected site

DSDaiichi Sankyo Europe GmbHPfaffenhofen A.D.Ilm, Germany

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 3 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere